Theravance Biopharma, Inc. Deferred Income Tax Expense (Benefit)
Theravance Biopharma, Inc. (TBPH) reported Deferred Income Tax Expense (Benefit) of -$11.52 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-23
- Theravance Biopharma, Inc. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $30.00K.
- Theravance Biopharma, Inc. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was $994.00K, a 1004.44% increase year-over-year.
- Theravance Biopharma, Inc. deferred income tax expense (benefit) for the quarter ending 2025-06-30 was -$10.69M.
- Theravance Biopharma, Inc. deferred income tax expense (benefit) for the quarter ending 2025-03-31 was -$1.85M.
- Theravance Biopharma, Inc. deferred income tax expense (benefit) for fiscal 2025 was -$11.52M.
- Theravance Biopharma, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$7.57M, a 336.14% decline from fiscal 2023.
- Theravance Biopharma, Inc. deferred income tax expense (benefit) for fiscal 2023 was $3.21M.
- Theravance Biopharma, Inc. deferred income tax expense (benefit) for fiscal 2017 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.02M derived: sum of 2 quarters · filed 2026-03-23 | -$9.67M derived: sum of 3 quarters · filed 2026-03-23 | -$11.52M 10-K · filed 2026-03-23 |
| 2025-09-30 | $994.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$9.70M derived: sum of 2 quarters · filed 2025-11-12 | -$11.55M 10-Q · filed 2025-11-12 | -$18.14M derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-06-30 | -$10.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$12.54M 10-Q · filed 2025-08-13 | -$19.13M derived: sum of 3 quarters · filed 2026-03-23 | -$19.04M derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-03-31 | -$1.85M 10-Q · filed 2025-05-12 | -$8.44M derived: sum of 2 quarters · filed 2026-03-23 | -$8.35M derived: sum of 3 quarters · filed 2026-03-23 | -$8.91M derived: sum of 4 quarters · filed 2026-03-23 |
| 2024-12-31 | -$6.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$6.50M derived: sum of 2 quarters · filed 2026-03-23 | -$7.06M derived: sum of 3 quarters · filed 2026-03-23 | -$7.57M 10-K · filed 2026-03-23 |
| 2024-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$471.00K derived: sum of 2 quarters · filed 2025-11-12 | -$984.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$561.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.07M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$513.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $3.21M 10-K · filed 2025-03-07 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-02-28 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-02-28 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-11 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |